Big Idea Ventures (BIV), via its Generation Food Rural Partners (GFRP) fund, and Mercantile Life Science Ventures IV have jointly invested in Maia Fertility, an Israel-based biotechnology company developing a sustained-release enzyme platform called Ferizyme™ aimed at improving reproductive outcomes in cattle — with a stated long-term pathway into human reproductive health.
For operators and buyers watching the food-and-agriculture supply chain, the investment signals continued institutional appetite for reproductive-efficiency technology in livestock — a segment with direct downstream implications for beef and dairy supply costs, herd productivity benchmarks, and the protein supply chains that feed foodservice.
Why Livestock Fertility Matters
Reproductive efficiency is one of the most significant cost levers in commercial cattle operations. Poor conception rates extend the time between calving cycles, inflate feed and management costs per head, and reduce the predictability of beef and dairy supply. Technology that meaningfully moves those metrics — particularly at scale across commercial farms — has compounding value for the supply chain from ranch to processor to distributor.
Ferizyme™ is designed as a sustained-release enzyme delivery system intended to address fertility bottlenecks in mammals. The company plans to use this funding round to complete efficacy studies on commercial farms in North America and Europe, refine the delivery mechanism, and begin building the healthcare infrastructure needed for eventual human applications. Tom Mastrobuoni, Chief Investment Officer at Big Idea Ventures, described the cattle market opportunity as "immediate" while calling the long-term human health pathway "transformative."
The Investor Angle
BIG IDEA Ventures manages more than 100 portfolio companies across 30 countries, with a focus on food, agriculture, and materials innovation. Its GFRP vehicle is an RBIC-licensed fund backed by Farm Credit System members — including CoBank, Farm Credit Services of America, Compeer Financial, and Mid-America Farm Credit — specifically designed to commercialize technologies developed at universities and research institutions and deploy them into rural markets. That structure makes GFRP a notable funding channel for ag-biotech companies seeking both capital and distribution infrastructure into production agriculture.
Mercantile Companies Inc., the Chicago-headquartered parent of MLSV, brings a portfolio spanning healthcare, wellness, agriculture, and technology. I. Steven Edelson, CEO of Mercantile Companies Inc., framed the investment around the dual utility of reproductive technology across both agricultural and clinical settings — a thesis that positions Ferizyme™ as a platform asset rather than a single-market product.
For foodservice procurement teams and protein buyers, investments at this stage of the ag-biotech stack are worth monitoring. Technologies that improve herd fertility rates affect the long-run economics of beef and dairy supply — factors that eventually surface in commodity pricing and contract negotiations. Operators managing large protein spend should track commercialization timelines as clinical studies progress through 2026 and into 2027.
For more context on where capital is flowing in the food-and-agriculture innovation stack, see our coverage of emerging protein supply chain investments and ag-tech procurement shifts.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
